Skip to main content

Table 2 Correlations between calprotectin, and other clinical and metabolic parameters in diabetic patients

From: Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy?

  BMI SBP DBP HDL-C LDL-C TG FBP HbA1C hsCRP
Calprotectin          
R 0.147 0.061 0.135 −0.166 −0.028 0.192 0.221 0.437 0.510
P 0.177 0.577 0.215 0.129 0.796 0.077 0.041 <0.001 <0.001
BMI          
R   0.237 0.146 0.097 0.126 −0.501 0.117 0.180 0.175
P   0.028 0.180 0.377 0.246 0.641 0.285 0.096 0.188
SBP          
R    0.611 0.228 0.239 −0.051 0.003 0.112 −0.030
P    <0.001 0.036 0.027 0.641 0.982 0.303 0.823
DBP          
R     0.259 0.155 −0.158 0.070 0.150 0.019
P     0.017 0.153 0.146 0.523 0.169 0.887
HDL-C          
R      0.460 0.077 0.391 0.271 −0.224
P      <0.001 0.484 <0.001 0.012 0.094
LDL-C          
R       0.171 0.224 0.070 −0.328
P       0.116 0.038 0.522 0.012
TG          
R        0.587 0.324 −0.047
P        <0.001 0.002 0.726
FBG          
R         0.729 0.207
P         <0.001 0.120
HbA1C          
R          0.203
P          0.127
  1. Data were expressed as median (±IQR) and *mean (±SD). Mann–Whitney U and *Student’s t-test was used in comparison of 2 independent group. DM with neuropath group, DNP (+); DM without neuropathy group, DNP (−); Healthy control group, HC; Body Mass Index, BMI; Systolic blood pressure, SBP; Diastolic blood pressure; Fasting blood glucose; High density lipoprotein cholesterol, HDL-C; Triglyceride, TG; Low density lipoprotein cholesterol, LDL-C; High sensitive C reactive protein, hsCRP; Oral antidiabetic drug, OAD.